Abeona Therapeutics Inc (ABEO.OQ)
ABEO.OQ on NASDAQ Stock Exchange Capital Market
13.25USD
17 Aug 2018
13.25USD
17 Aug 2018
Change (% chg)
$-0.45 (-3.28%)
$-0.45 (-3.28%)
Prev Close
$13.70
$13.70
Open
$13.85
$13.85
Day's High
$14.25
$14.25
Day's Low
$13.00
$13.00
Volume
155,641
155,641
Avg. Vol
202,705
202,705
52-wk High
$22.70
$22.70
52-wk Low
$7.50
$7.50
About
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin... (more)
Overall
| Beta: | 2.29 |
| Market Cap(Mil.): | $713.08 |
| Shares Outstanding(Mil.): | 40.29 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ABEO.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.68 | 32.76 |
| EPS (TTM): | -0.60 | -- | -- |
| ROI: | -29.33 | 1.78 | 14.61 |
| ROE: | -30.75 | 3.28 | 16.33 |
BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia
* ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA
BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease
* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:
BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer
* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER
BRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer
* TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:
BRIEF-Abeona Therapeutics Reports Q4 Loss Per Share $0.19
* ABEONA THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease
* ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE
Competitors
| Price | Chg | |
|---|---|---|
| Amgen, Inc. (AMGN.OQ) | $197.42 | +0.98 |
| Curagen Corp (CRGN.OQ) | -- | -- |
| OSI Pharmaceuticals, Inc. (OSIP.OQ) | -- | -- |
| Bristol-Myers Squibb Co (BMY.N) | $60.89 | -0.22 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $999.90 | -- |
| Sanofi SA (SASY.PA) | €73.30 | -- |
| Agenus Inc (AGEN.OQ) | $1.67 | -0.03 |
| Poniard Pharmaceuticals, Inc. (PARD.PK) | $0.05 | 0.00 |
| NanoCarrier Co., Ltd. (4571.T) | ¥523 | +23.00 |
| Enzon Pharmaceuticals Inc (ENZN.PK) | $0.26 | -0.00 |
Estimates